Host-Related Factors in the Interplay Among Inflammation, Immunity and Dormancy in Breast Cancer Recurrence and Prognosis: An Overview for Clinicians

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Mar 11

PMID 36902406

Authors

Lorenzo Ruggieri

Anna Moretti

Rossana Berardi

Maria Silvia Cona

Davide Dalu

Cecilia Villa

Davide Chizzoniti

Sheila Piva

Anna Gambaro

Nicla La Verde

Affiliations

Soon will be listed here.

Abstract

A significant proportion of patients treated for early breast cancer develop medium-term and late distant recurrence. The delayed manifestation of metastatic disease is defined as "dormancy". This model describes the aspects of the clinical latency of isolated metastatic cancer cells. Dormancy is regulated by extremely complex interactions between disseminated cancer cells and the microenvironment where they reside, the latter in turn influenced directly by the host. Among these entangled mechanisms, inflammation and immunity may play leading roles. This review is divided into two parts: the first describes the biological underpinnings of cancer dormancy and the role of the immune response, in particular, for breast cancer; the second provides an overview of the host-related factors that may influence systemic inflammation and immune response, subsequently impacting the dynamics of breast cancer dormancy. The aim of this review is to provide physicians and medical oncologists a useful tool to understand the clinical implications of this relevant topic.

Citing Articles

Effects of T2DM on cancer progression: pivotal precipitating factors and underlying mechanisms.

Zhang Y, Li Y, Xue C, Li S, Gao Z, Qin K Front Endocrinol (Lausanne). 2024; 15:1396022.

PMID: 39290325 PMC: 11405243. DOI: 10.3389/fendo.2024.1396022.

References

Malladi S, Macalinao D, Jin X, He L, Basnet H, Zou Y . Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT. Cell. 2016; 165(1):45-60. PMC: 4808520. DOI: 10.1016/j.cell.2016.02.025. View

Lan Q, Peyvandi S, Duffey N, Huang Y, Barras D, Held W . Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer. Oncogene. 2018; 38(15):2814-2829. PMC: 6477891. DOI: 10.1038/s41388-018-0624-2. View

Semenza G . Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3(10):721-32. DOI: 10.1038/nrc1187. View

Gao H, Chakraborty G, Lee-Lim A, Mo Q, Decker M, Vonica A . The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell. 2012; 150(4):764-79. PMC: 3711709. DOI: 10.1016/j.cell.2012.06.035. View

Albrengues J, Shields M, Ng D, Park C, Ambrico A, Poindexter M . Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science. 2018; 361(6409). PMC: 6777850. DOI: 10.1126/science.aao4227. View

Yang H, Villani R, Wang H, Simpson M, Roberts M, Tang M . The role of cellular reactive oxygen species in cancer chemotherapy. J Exp Clin Cancer Res. 2018; 37(1):266. PMC: 6211502. DOI: 10.1186/s13046-018-0909-x. View

La Verde N, Collova E, Blasi L, Pinotti G, Palumbo R, Bonotto M . Overall Survival in Metastatic Breast Cancer Patients in the Third Millennium: Results of the COSMO Study. Clin Breast Cancer. 2020; 21(5):e489-e496. DOI: 10.1016/j.clbc.2020.11.001. View

Sestak I, Distler W, Forbes J, Dowsett M, Howell A, Cuzick J . Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol. 2010; 28(21):3411-5. DOI: 10.1200/JCO.2009.27.2021. View

Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P . Breast cancer. Nat Rev Dis Primers. 2019; 5(1):66. DOI: 10.1038/s41572-019-0111-2. View

10.

Mazzarella L, Disalvatore D, Bagnardi V, Rotmensz N, Galbiati D, Caputo S . Obesity increases the incidence of distant metastases in oestrogen receptor-negative human epidermal growth factor receptor 2-positive breast cancer patients. Eur J Cancer. 2013; 49(17):3588-97. DOI: 10.1016/j.ejca.2013.07.016. View

11.

Montagner M, Bhome R, Hooper S, Chakravarty P, Qin X, Sufi J . Crosstalk with lung epithelial cells regulates Sfrp2-mediated latency in breast cancer dissemination. Nat Cell Biol. 2020; 22(3):289-296. PMC: 7610690. DOI: 10.1038/s41556-020-0474-3. View

12.

Pavlovic M, Arnal-Estape A, Rojo F, Bellmunt A, Tarragona M, Guiu M . Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis. J Natl Cancer Inst. 2015; 107(12):djv256. PMC: 4681582. DOI: 10.1093/jnci/djv256. View

13.

Uzuner D, Akkoc Y, Peker N, Pir P, Gozuacik D, Cakir T . Transcriptional landscape of cellular networks reveal interactions driving the dormancy mechanisms in cancer. Sci Rep. 2021; 11(1):15806. PMC: 8339123. DOI: 10.1038/s41598-021-94005-x. View

14.

Shor R, Dai J, Lee S, Pisarsky L, Matei I, Lucotti S . The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settings. Mol Oncol. 2021; 16(1):130-147. PMC: 8732345. DOI: 10.1002/1878-0261.13031. View

15.

Kozlow W, Guise T . Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia. 2005; 10(2):169-80. DOI: 10.1007/s10911-005-5399-8. View

16.

Nelson M, Madsen S, Cooke K, Fritzen A, Thorius I, Masson S . Systems-level analysis of insulin action in mouse strains provides insight into tissue- and pathway-specific interactions that drive insulin resistance. Cell Metab. 2022; 34(2):227-239.e6. DOI: 10.1016/j.cmet.2021.12.013. View

17.

Baldominos P, Barbera-Mourelle A, Barreiro O, Huang Y, Wight A, Cho J . Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche. Cell. 2022; 185(10):1694-1708.e19. PMC: 11332067. DOI: 10.1016/j.cell.2022.03.033. View

18.

Goodwin P, Ennis M, Pritchard K, Trudeau M, Koo J, Taylor S . Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations. J Clin Oncol. 2011; 30(2):164-71. DOI: 10.1200/JCO.2011.36.2723. View

19.

Lawlor D, Davey Smith G, Ebrahim S . Hyperinsulinaemia and increased risk of breast cancer: findings from the British Women's Heart and Health Study. Cancer Causes Control. 2004; 15(3):267-75. DOI: 10.1023/B:CACO.0000024225.14618.a8. View

20.

Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C . Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002; 62(3):632-5. View